Söndag 23 Februari | 22:30:04 Europe / Stockholm

Prenumeration

2025-02-14 09:46:00

Redeye provides an update following SenzaGen’s Q4 2024 report. The sales during the quarter were disappointing, although we maintain that the long-term investment case remains intact. We have made sales estimate adjustments, which is the main reason for our lowered fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/